NASH/MASH Treatment Market Opportunity in Obesity-Co-Morbidity Therapies and GLP 1 Combo Approaches

"The Global NASH/MASH Treatment Market reached US$7.87 billion in 2024 and is expected to reach US$31.76 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033," according to DataM Intelligence. The approved drugs market value is reported at US$178.31 million in 2024 and is expected to reach US$16.82 billion in 2033, growing at a CAGR of 57.05%.

As per our analysis, the NASH/MASH Treatment Market is spearheaded by Madrigal Pharmaceuticals (with its first-in-class drug resmetirom/Rezdiffra). Emerging biotech contenders include Novo Nordisk, Boehringer Ingelheim, 89bio, Inventiva, Chia Tai Tianqing, Sagimet Biosciences, and Akero Therapeutics, focusing on advanced small molecules, RNAi agents, PPAR agonists, and liver fibrosis inhibitors. Together, they foster a dynamic market with strong R&D innovation and regulatory breakthroughs.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market?jd

NASH/MASH Treatment Market M&A & Strategic Collaborations

• Madrigal secures U.S. patent for Rezdiffra until 2044, strengthening its market exclusivity in NASH/MASH therapy.
• Inventiva's Lanifibranor maintains Phase III momentum under Breakthrough status, supported by recent pipeline reports.
• Madrigal completes patient enrollment in cirrhosis trial (Phase III), advancing its MASH indication.

These highlights demonstrate a surge in patent fortification, Phase III data progression, and clinical expansion in the NASH/MASH market rather than traditional M&A.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nash-or-mash-treatment-market?jd

Key Growth Drivers & Emerging Opportunities in the NASH/MASH Treatment Market

• Rezdiffra enjoys blockbuster launch, with Q1 2025 sales of USD 137.3 million and over 17,000 patients treated.
• Strong pipeline advancement: Pan-PPAR agonist lanifibranor (Breakthrough/FTD in Phase III) and RNAi/ASO candidates (ARO-HSD, AZD2693) progress.
• Rising NASH prevalence, linked to obesity and diabetes, supports robust therapeutic demand.
• Biotech-biologic partnerships accelerate commercialization of next-gen targets (e.g., fibrosis, metabolic endpoints, GLP-1 combos).
• Strategic patent positioning and EU conditional approvals expand addressable patient populations globally.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nash-or-mash-treatment-market?jd

Regional Market Drivers in the NASH/MASH Treatment Market

North America leads, propelled by Rezdiffra's FDA approval, widespread NASH screening, and payer adoption.
Europe builds groundwork via EMA conditional authorization of Resmetirom and late-stage trial entries.
Asia-Pacific emerges with RNAi therapies, biosimilars, and obesity-linked disease management fueling pipeline interest.
LATAM & MEA show expansion due to rising metabolic disorder prevalence and increasing trial participation in emerging disease areas.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis for Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.